HomeSectors Biotechnology

Biotechnology

Cochlear HY26 Financial Results Show Nexa Rollout Impact

Neuren Pharmaceuticals Welcomes Reauthorisation of US Priority Review Voucher Program

Neuren Pharmaceuticals Confirms Daybue Sales Outlook After ASX Aware Letter

Affordable £2.50 Drug Extends Lives of Prostate Cancer Patients

JPMorgan Healthcare Conference 2026 Breaks Ground On Pharma Frontiers

Aged Care Crisis Australia Deepens As Allman-Payne Blasts Health Officials Over System Failures

Could This Common Drug Stop One of Childhood’s Deadliest Cancers?

Popular Hair Loss Medication Hides Dark Secret: Men Face Suicide Risk After Treatment

Medibank’s Bold Vision: Doubling Health Engagement to 10 Million by 2030

Botanix Pharmaceuticals Sofdra Revenue Surges 65% In Q1 FY26

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑

Biotechnology

Recent Posts

Categories

Disclaimer

Categories

Trending Posts